JPRN-UMIN000008631
Completed
Phase 2
Multi-center, phase II study for combination therapy with weekly pacritaxel and 5'-DFUR in patients with unresectable or recurrent gastric cancer - Multi-center, phase II study for combination therapy with weekly pacritaxel and 5'-DFUR in patients with unresectable or recurrent gastric cancer
Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine0 sites45 target enrollmentAugust 6, 2012
ConditionsAdvanced or recurrent gastric cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Advanced or recurrent gastric cancer
- Sponsor
- Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine
- Enrollment
- 45
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Drug hypersensitivity. 2\) Infection and inflammation. 3\) Prior infusion of paclitaxel 4\) Peripheral neuropathy 5\) Active synchronous malignancy. 6\) Brain metastasis. 7\) Severe mental disorders. 8\) Symptomatic pulmonary fibrosis or interstitial pneumonia. 9\) Severe systemic edema. 10\) A large amount of pleural effusion or peritoneal fluid. 11\) Severe heart disease. 12\) Myocardial infarction within six months. 13\) DM with insulin injection. 14\) Pregnant patient
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with metastatic gastric cancerElderly patients with metastatic gastric cancerJPRN-UMIN000009349ational Cancer Center Hospital40
Completed
Phase 2
Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)Colorectal cancerJPRN-UMIN000012063Kurume University Medical Center30
Recruiting
Phase 2
Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancercolorectal cancerJPRN-UMIN000006793ippon Medical School Musashikosugi Hospital40
Not yet recruiting
Phase 2
Phase II clinical trial of multidisciplinary therapy using risk classification based on residual tumor volume and WHO grading for pediatric ependymoma patients (JCCG EPN1501)JPRN-UMIN000023803The Japan Children's Cancer Group(JCCG)40
Completed
Phase 2
A phase II study of TAS-102 and RamucirumabJPRN-jRCT2080224529Taiho Pharmaceutical Co., Ltd.60